BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11333278)

  • 1. Promoter hypermethylation--can this change alone ever designate true tumor suppressor gene function?
    Baylin SB; Herman JG
    J Natl Cancer Inst; 2001 May; 93(9):664-5. PubMed ID: 11333278
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation.
    Allinen M; Peri L; Kujala S; Lahti-Domenici J; Outila K; Karppinen SM; Launonen V; Winqvist R
    Genes Chromosomes Cancer; 2002 Aug; 34(4):384-9. PubMed ID: 12112527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
    Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
    J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
    Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
    Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.
    Dammann R; Takahashi T; Pfeifer GP
    Oncogene; 2001 Jun; 20(27):3563-7. PubMed ID: 11429703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
    Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
    Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene.
    Cheng CW; Wu PE; Yu JC; Huang CS; Yue CT; Wu CW; Shen CY
    Oncogene; 2001 Jun; 20(29):3814-23. PubMed ID: 11439345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.
    Fukami T; Fukuhara H; Kuramochi M; Maruyama T; Isogai K; Sakamoto M; Takamoto S; Murakami Y
    Int J Cancer; 2003 Oct; 107(1):53-9. PubMed ID: 12925956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines.
    Patel AC; Anna CH; Foley JF; Stockton PS; Tyson FL; Barrett JC; Devereux TR
    Carcinogenesis; 2000 Sep; 21(9):1691-700. PubMed ID: 10964101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
    Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
    Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
    Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
    Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
    Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
    Dammann R; Yang G; Pfeifer GP
    Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.
    Carvalho AL; Chuang A; Jiang WW; Lee J; Begum S; Poeta L; Zhao M; Jerónimo C; Henrique R; Nayak CS; Park HL; Brait MR; Liu C; Zhou S; Koch W; Fazio VM; Ratovitski E; Trink B; Westra W; Sidransky D; Moon CS; Califano JA
    Cancer Res; 2006 Oct; 66(19):9401-7. PubMed ID: 17018594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
    Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
    Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.